# Study of ARO-AAT in Normal Adult Volunteers

> **NCT03362242** · PHASE1 · COMPLETED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** ARO-AAT Injection
- **OTHER:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT03362242
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-12
- **Primary completion:** 2018-10-23
- **Final completion:** 2020-03-21
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362242, "Study of ARO-AAT in Normal Adult Volunteers". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03362242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*